• Home
  1. Home
  2. Imatinib remains the best frontline therapy in patients with chronic myeloid leukemia : Critical analysis of the ASC4FIRST trial
Scientific article
Letter
OA Policy
English

Imatinib remains the best frontline therapy in patients with chronic myeloid leukemia : Critical analysis of the ASC4FIRST trial

ContributorsSrinivasan, Nethraorcid; Olivier, Timothéeorcid; Haslam, Alysonorcid; Prasad, Vinayorcid
Published inAmerican journal of hematology, vol. 99, no. 12, p. 2392-2394
Publication date2024-12
First online date2024-09-28
Affiliation entities
Citation (ISO format)
SRINIVASAN, Nethra et al. Imatinib remains the best frontline therapy in patients with chronic myeloid leukemia : Critical analysis of the ASC4FIRST trial. In: American journal of hematology, 2024, vol. 99, n° 12, p. 2392–2394. doi: 10.1002/ajh.27477
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
Additional URL for this publicationhttps://onlinelibrary.wiley.com/doi/10.1002/ajh.27477
Journal ISSN0361-8609
21views
125downloads

Technical informations

Creation25/02/2025 11:06:38
First validation19/03/2025 13:58:14
Update19/03/2025 13:58:14
Status update19/03/2025 13:58:14
Last indexation19/03/2025 13:58:15
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack